Texas Attorney General Ken Paxton is taking major insulin manufacturers and pharmacy benefit managers, known as PBMs, to court. Accused of colluding to hike up insulin prices, entities including Eli Lilly, Express Scripts, CVS Pharmacy, and others are being sued over what Paxton describes as a disturbing conspiracy. According to a lawsuit filed by the Texas Attorney General, these companies allegedly manipulated the insulin market to artificially inflate prices and engaged in questionable activities that might violate the Texas Deceptive Trade Practices Act. This suit claims that the price of insulin has soared up to 1,000% over the last decade, a burden unjustifiably shouldered by diabetes patients.
With insulin production costs reported under $2 and initial market prices around $20 in the late 1990s, current prices range from $300 to $700. This massive increase, as alleged in the lawsuit, results from a back-and-forth game of profits and incentives between the drug manufacturers and PBMs. Preferred status was granted to the insulin brands with the highest price tags, effectively excluding more affordable options. In launching this legal challenge, Paxton aims to tackle what he called the illegal and unethical enrichment of both Big Pharma and PBMs at the expense of diabetics in Texas, as reported by the Texas Attorney General's office.
Financial reciprocation between the involved parties ensured that expensive insulin drugs were standard offerings by the PBMs. These rebate payments were significant but undisclosed, fueling a market where transparency was clouded by private interests. "These companies acted illegally and unethically to enrich themselves, and we will hold them accountable," said Attorney General Paxton in a statement obtained by the Texas Attorney General's office. The lawsuit outlines that while PBMs claim to work in the interests of their clients and diabetics, aiming to lower drug prices and ensure access to affordable treatments, this portrayal seems contrary to their activities in practice which, in reality, skewed the market in their favor.
It’s not just about the money—healthcare access and the welfare of diabetics are also on the line here. The suit suggests that PBMs' representation of promoting diabetic health is undermined by these practices which inflate costs detrimental to the very patients they serve. Liston & Deas, David Nutt & Associates, the Cicala Law Firm, and Foreman Watkins Krutz are named as the outside counsel supporting the state of Texas. This legal maneuver by Paxton's office stands as a defiance against the alleged deceit and manipulation by some of the biggest names in the pharmaceutical industry, signaling a fight for justice in the realm of healthcare affordability.
